Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia in Eosinophilic Esophagitis Patients
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization
Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
Equity Metals Reports Assays from 2026 Validation Drilling on the No. 3 Vein and Active Q4 Exploration Initiatives, Silver Queen Project, BC
